Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting $\beta_2$ agonists

H J van der Woude, T H Winter, R Aalbers

Abstract
Background—In vitro the long acting $\beta_2$ agonist salmeterol can, in contrast to formoterol, behave as a partial agonist and become a partial antagonist to other $\beta_2$ agonists. To study this in vivo, the bronchodilating effect of salbutamol was measured during methacholine induced moderate to severe bronchoconstriction in patients receiving maintenance treatment with high dose long acting $\beta_2$ agonists.

Methods—A randomised double blind crossover study was performed in 19 asthmatic patients with mean forced expiratory volume in one second (FEV$_1$) of 88.4% predicted and median concentration of methacholine provoking a fall in FEV$_1$ of 20% or more (PC$_{20}$) of 0.62 mg/ml at entry. One hour after the last dose of 2 weeks of treatment with formoterol (24 µg twice daily by Turbuhaler), salmeterol (100 µg twice daily by Diskhaler), or placebo a methacholine provocation test was performed and continued until there was at least a 30% decrease in FEV$_1$. Salbutamol (50 µg) was administered immediately thereafter, followed by ipratropium bromide (40 µg) after a further 30 minutes. Lung function was monitored for 1 hour after provocation.

Results—There was a significant bronchodilating and bronchoprotective effect after 2 weeks of active treatment. The dose of methacholine needed to provoke a fall in FEV$_1$ of $\geq$30% was higher after pretreatment with formoterol (2.48 mg) than with salmeterol (1.58 mg) or placebo (0.74 mg). The difference between formoterol and salmeterol was statistically significant: 0.7 doubling dose steps (95% CI 0.1 to 1.2, p=0.016). The immediate bronchodilating effect of subsequently administered salbutamol was significantly impaired after pretreatment with both drugs (p<0.0003 for both). Three minutes after inhaling salbutamol the increase in FEV$_1$ relative to the pre-methacholine baseline was 15.8%, 7.3%, and 5.5% for placebo, formoterol and salmeterol, respectively (equivalent to increases of 26%, 14%, and 12%, respectively, from the lowest FEV$_1$ after methacholine). At 30 minutes significant differences remained, but 1 hour after completing the methacholine challenge FEV$_1$ had returned to baseline values in all three treatment groups.

Conclusion—Formoterol has a greater intrinsic activity than salmeterol as a bronchoprotective agent, indicating that salmeterol is a partial agonist compared with formoterol in contracted human airways in vivo. Irrespective of this, prior long term treatment with both long acting $\beta_2$ agonists reduced the bronchodilating effect of an additional single dose of salbutamol equally, indicating that the development of tolerance or high receptor occupancy overshadowed any possible partial antagonistic activity of salmeterol. Patients on regular treatment with long acting $\beta_2$ agonists should be made aware that an additional single dose of a short acting $\beta_2$ agonist may become less effective.

Thorax 2001;56:529–535

Keywords: formoterol; salmeterol; salbutamol; asthma; tolerance

Inhaled $\beta_2$ agonists are extensively used in the treatment of asthma due to their excellent bronchodilating and bronchoprotective effects. As the duration of action of the two newest $\beta_2$ agonists, salmeterol and formoterol, is longer than of the older $\beta_2$ agonists, they are classified as long acting $\beta_2$ agonists. Both salmeterol and formoterol have an established position in the maintenance treatment of moderate to severe asthma, with short acting $\beta_2$ agonists being used additionally “as needed”.

Salmeterol and formoterol differ pharmacologically in that formoterol has a much faster onset of action than salmeterol and, in vitro, salmeterol is a partial agonist on the $\beta_2$ receptor while formoterol is virtually a full agonist. During strong cholinergic bronchoconstriction, salmeterol has been shown to behave as an antagonist towards subsequently administered $\beta_2$ agonists. In vivo, such cholinergic bronchoconstriction may exist during an acute asthma attack.

Many studies have focused on tachyphylaxis and tolerance during treatment with $\beta_2$ agonists. This phenomenon appears to have a stronger effect after continued treatment of the $\beta_2$ agonist than after a single dose.

In this study we have investigated whether formoterol and salmeterol, given in high doses, behave as antagonists to subsequently given...
Table 1 Characteristics of patients

<table>
<thead>
<tr>
<th>Sex (female/male)</th>
<th>15/4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>38 (7), (24–49)</td>
</tr>
<tr>
<td>FEV1 (l)</td>
<td>2.88 (0.66), (1.74–3.98)</td>
</tr>
<tr>
<td>FEV1 (% predicted)</td>
<td>88.4 (16.1), (63–111)</td>
</tr>
<tr>
<td>P&lt;sub&gt;20&lt;/sub&gt; methacholine (mg/ml)</td>
<td>0.62 (0.06–4.30)</td>
</tr>
<tr>
<td>P&lt;sub&gt;D30+&lt;/sub&gt; methacholine (mg)</td>
<td>0.77 (0.18–3.18)</td>
</tr>
<tr>
<td>Inhaled steroid dose (µg/day)</td>
<td>500 (400–1600)</td>
</tr>
</tbody>
</table>

Values are presented as absolute numbers or as mean (SD), (range) except P<sub>20</sub>, P<sub>D30+</sub> and steroid dose where a median (range) is given.

FEV<sub>1</sub> = forced expiratory volume in 1 second; P<sub>20</sub>, P<sub>D30+</sub> = provocative concentration of methacholine causing a decrease in FEV<sub>1</sub> of 20%; P<sub>D30+</sub> = provocative dose of methacholine causing decrease in FEV<sub>1</sub> of ≥30%.

Table 2 Mean (SD) forced expiratory volume in one second (FEV<sub>1</sub>) in litres on the three test days before and after the morning dose, at reaching a methacholine induced decrease in FEV<sub>1</sub> of ≥30%, at 3 and 30 minutes after salbutamol inhalation, and at 30 minutes after additional ipratropium bromide inhalation

<table>
<thead>
<tr>
<th></th>
<th>Pre-dose</th>
<th>Post-dose (baseline)</th>
<th>After methacholine (t = 0 min)</th>
<th>After salbutamol (t = 3 min)</th>
<th>After salbutamol (t = 30 min)</th>
<th>After additional ipratropium (t = 60 min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formoterol (n=17)</td>
<td>2.82 (0.72)</td>
<td>2.99 (0.74)</td>
<td>1.73 (0.52)</td>
<td>1.94 (0.54)*</td>
<td>2.50 (0.71)*</td>
<td>2.90 (0.75)</td>
</tr>
<tr>
<td>Salmeterol (n=16)</td>
<td>2.80 (0.69)</td>
<td>2.98 (0.73)</td>
<td>1.83 (0.56)</td>
<td>2.00 (0.54)*</td>
<td>2.57 (0.65)*</td>
<td>2.94 (0.77)</td>
</tr>
<tr>
<td>Placebo (n=16)</td>
<td>2.65 (0.67)</td>
<td>2.67 (0.65)</td>
<td>1.68 (0.46)</td>
<td>2.10 (0.56)</td>
<td>2.68 (0.67)</td>
<td>2.94 (0.75)</td>
</tr>
</tbody>
</table>

*p<0.05 compared with placebo (significance only tested at 3 and 30 minutes).

The study was approved by the medical ethics committee of the Martini Hospital, Groningen, the Netherlands and was conducted according to Good Clinical Practice Guidelines. Written informed consent was obtained from all patients prior to enrolment.

STUDY DESIGN

This double blind, randomised, crossover study used a double dummy technique for administering study drugs. The enrolment visit and each of the three test days were separated by three treatment periods of 2 weeks.

Inhalers with formoterol (blinded Oxis Turbuhaler, 12 µg formoterol fumarate per metered dose mixed with lactose, equivalent to 9 µg delivered dose), salmeterol (blinded Ser-event Diskhaler, 50 µg salmeterol xinafoate per dose mixed with lactose), and placebo (lactose) were provided by AstraZeneca R&D Lund. Two doses from each of two inhalers were administered twice daily over 2 weeks, starting in the evening after a visit day and using the last dose on the morning of the clinic visit, after measuring FEV<sub>1</sub>. The daily dosages were thus 48 µg formoterol and 200 µg salmeterol. The 1:4 relationship has previously been reported to result in approximately equal bronchodilation; the high dose was applied to ensure maximal bronchodilation. Ipratropium bromide was allowed as rescue medication (40 µg Atrovent capsules administered via Inhalator Ingenheim, Boehringer Ingelheim, the Netherlands).

No washout period was deemed necessary since it was expected that a new steady state situation would be attained within 1 week. Before each visit the patients had not taken inhaled ipratropium bromide, inhaled glucocorticosteroids, or cromoglycate in the previous 2 hours, nor caffeine containing beverages in the previous 2 hours. They also refrained from exercise before the tests.

A test day was postponed if morning FEV<sub>1</sub> was below 80% or above 120% of the baseline FEV<sub>1</sub> at enrolment. In the morning of the three test days pre-dose lung function was measured, followed by the last dose of study medication. One hour later lung function was again measured—referred to hereafter as the post-dose and “baseline” lung function—and the methacholine provocation test started. The provocation tests were scheduled within 1 hour of the time at which they were performed during the enrolment visit. The same technician performed all tests. At the initial visit the patients practised their inhalation technique with empty inhalers in accordance with the manufacturers’ instructions. At the screening visit and 1 hour after the morning dose on the three test days a standard methacholine provocation test was performed and continued until a reduction of at least 30% in FEV<sub>1</sub> was achieved. The challenges were performed using a Wiesbadener Doppelinhalator giving an output of 0.2 ml in 2 minutes. After saline, doubling concentrations of methacholine bromide from 0.125 mg/ml to 64 mg/ml dissolved in saline were inhaled at 5 minute intervals during 2 minutes of tidal breathing. FEV<sub>1</sub> was measured with a dry spirometer (Schiller...
The primary parameter in the statistical analysis was the increase in FEV₁ from 0 to 3 minutes after inhaling salbutamol, expressed as % of the baseline value (post-dose FEV₁). Secondary parameters (FEV₁ at 30 and at 60 minutes, PC₂₀ methacholine, PD₃₀⁺ methacholine, and the recovery time) were statistically analysed to a limited extent to prevent false positive conclusions. The PC₂₀ was calculated by linear interpolation of the log methacholine concentration (non-cumulative) versus the percentage fall in FEV₁ from baseline. The cumulative methacholine dose administered to induce the PD₃₀⁺ was calculated from the nebuliser output, arbitrarily assuming that all methacholine nebulised during 2 minutes penetrated into the lungs. The recovery time was calculated from the data points immediately before and after FEV₁ returned to 85% of baseline by linear interpolation. In cases where FEV₁ did not return to 85% of baseline within 60 minutes, an arbitrary time of 75 minutes was used in the analyses. For the statistical analysis of PC₂₀, PD₃₀⁺ and the recovery time a log transformation was made. If the lowest methacholine dose caused a decrease in FEV₁ of 20% or more, PC₂₀ was arbitrarily set at half the lowest concentration—that is, 0.0625 mg/ml.

Analysis of covariance (ANCOVA) was used to determine treatment differences with patient, period, and treatment as factors. The observed maximal percentage decreases in FEV₁, and PD₃₀⁺, were used as covariates since both the magnitude of the fall in FEV₁ and the methacholine dose could be expected to have an influence on the recovery of FEV₁ at 3 minutes and the recovery time. When a covariate was not statistically significant it was excluded from the analyses. A two sided p value of <0.05 was considered significant. When treatment was statistically significant, 95% confidence intervals (95% CI) were calculated from the least squares means. Differences in PC₂₀ and PD₃₀⁺ between treatments are expressed as doubling dose steps, originating from analyses from base-2 log transformed data.
The absolute FEV\textsubscript{1} values on test days are shown in table 2 and the percentage predicted FEV\textsubscript{1} during the entire test day is shown in fig 1. At the start of the test day, approximately 12 hours after inhaling the previous evening dose, pre-dose FEV\textsubscript{1} values in the formoterol and salmeterol periods were 0.151 and 0.121 higher, respectively, than in the placebo period. One hour after the morning dose the differences were 0.321 and 0.261 (approximately 10%, statistical significance not tested). Compared with placebo, more methacholine had to be administered following active treatment before FEV\textsubscript{1} decreased by 20% and by \geq 30% from baseline. The PC\textsubscript{20} values after formoterol and salmeterol administration differed by 1.5 doubling dose steps (95% CI 0.8 to 2.1) and 1.0 doubling dose step (95% CI 0.3 to 1.7), respectively, both differences being statistically significant. The values between active treatments did not differ significantly (0.5 doubling dose steps, 95% CI –0.2 to 1.1). PD\textsubscript{30+} differed in a similar way; geometric mean PD\textsubscript{30+} was 2.48 mg after formoterol treatment, 1.58 mg after salmeterol pretreatment, and 0.74 mg after placebo pretreatment (fig 2). The difference in PD\textsubscript{30+} of 0.7 doubling dose steps between the two active treatments was statistically significant (95% CI 0.1 to 1.2, p=0.016).

Apart from the difference in methacholine dose, the provocation tests on the three test days were comparable with a mean overall decrease in FEV\textsubscript{1} of 39.3% from baseline (ranging from 29.8% to 61.3% on individual days).

Three minutes after inhaling salbutamol FEV\textsubscript{1} increased by a mean (SD) of 15.8 (9.7)% of the baseline (pre-challenge) value after pretreatment with placebo compared with 7.3 (8.4)% after pretreatment with formoterol and 5.5 (8.9)% after pretreatment with salmeterol (p=0.0003 for both treatments, ANCOVA). The covariate actual % decrease in FEV\textsubscript{1} was statistically significant (p=0.014) whereas the covariate PD\textsubscript{30+} was not (p=0.12). The difference in FEV\textsubscript{1} between pretreatment with placebo and with active drug was 11.9% (95% CI 6.1 to 17.7) for formoterol and 11.3% (95% CI 5.7 to 16.9) for salmeterol (both p=0.0003). The difference between the two active pretreatments was not significant (95% CI –6.2 to 5.0, p=0.82). In a post hoc analysis comparing only the two active treatments and taking PD\textsubscript{30+} as covariate, the difference between the two long acting \beta\textsubscript{2} agonists remained not significant, nor was the covariate significant. The percentage increase in FEV\textsubscript{1}, from the lowest FEV\textsubscript{1} after methacholine was 14 (19)%, 12 (21)% and 26 (17)% after pretreatment with formoterol, salmeterol, and placebo, respectively (fig 3). Thirty minutes after inhaling salbutamol the increase in FEV\textsubscript{1} was still significantly smaller after both active pretreatments than after placebo (p=0.0001, ANCOVA), with again no significant difference between the two active treatments. Following all three pretreatments the mean FEV\textsubscript{1} returned to

It was estimated that 20 enrolled subjects were needed to give at least 15 subjects who could be fully evaluated. The effect at 3 minutes was considered to be the primary parameter in the analysis. A power calculation, using the results of a previous study,\textsuperscript{4} indicated that a difference of 4% could be detected in the increase in FEV\textsubscript{1}, after 3 minutes with a significance level of 5% and a power of 80%.

**Results**

Nineteen patients were enrolled in the study and randomised. Four patients were withdrawn because of concurrent airway infections; all four were comparable to the other 15 patients in baseline lung function and PC\textsubscript{20} methacholine. The provocation tests were well tolerated and there was no need for an additional bronchodilator. Table 1 shows the patient characteristics; the patients can be regarded as having mild to moderate asthma but with pronounced bronchial hyperresponsiveness.

The absolute FEV\textsubscript{1} values on test days are shown in table 2 and the percentage predicted FEV\textsubscript{1} during the entire test day is shown in fig 1. At the start of the test day, approximately 12 hours after inhaling the previous evening dose, pre-dose FEV\textsubscript{1} values in the formoterol and salmeterol periods were 0.151 and 0.121 higher, respectively, than in the placebo period. One hour after the morning dose the differences were 0.321 and 0.261 (approximately 10%, statistical significance not tested). Compared with placebo, more methacholine had to be administered following active treatment before FEV\textsubscript{1} decreased by 20% and by \geq 30% from baseline. The PC\textsubscript{20} values after formoterol and salmeterol administration differed by 1.5 doubling dose steps (95% CI 0.8 to 2.1) and 1.0 doubling dose step (95% CI 0.3 to 1.7), respectively, both differences being statistically significant. The values between active treatments did not differ significantly (0.5 doubling dose steps, 95% CI –0.2 to 1.1). PD\textsubscript{30+} differed in a similar way; geometric mean PD\textsubscript{30+} was 2.48 mg after formoterol treatment, 1.58 mg after salmeterol pretreatment, and 0.74 mg after placebo pretreatment (fig 2). The difference in PD\textsubscript{30+} of 0.7 doubling dose steps between the two active treatments was statistically significant (95% CI 0.1 to 1.2, p=0.016).

Apart from the difference in methacholine dose, the provocation tests on the three test days were comparable with a mean overall decrease in FEV\textsubscript{1} of 39.3% from baseline (ranging from 29.8% to 61.3% on individual days).

Three minutes after inhaling salbutamol FEV\textsubscript{1} increased by a mean (SD) of 15.8 (9.7)% of the baseline (pre-challenge) value after pretreatment with placebo compared with 7.3 (8.4)% after pretreatment with formoterol and 5.5 (8.9)% after pretreatment with salmeterol (p=0.0003 for both treatments, ANCOVA). The covariate actual % decrease in FEV\textsubscript{1} was statistically significant (p=0.014) whereas the covariate PD\textsubscript{30+} was not (p=0.12). The difference in FEV\textsubscript{1} between pretreatment with placebo and with active drug was 11.9% (95% CI 6.1 to 17.7) for formoterol and 11.3% (95% CI 5.7 to 16.9) for salmeterol (both p=0.0003). The difference between the two active pretreatments was not significant (95% CI –6.2 to 5.0, p=0.82). In a post hoc analysis comparing only the two active treatments and taking PD\textsubscript{30+} as covariate, the difference between the two long acting \beta\textsubscript{2} agonists remained not significant, nor was the covariate significant. The percentage increase in FEV\textsubscript{1}, from the lowest FEV\textsubscript{1} after methacholine was 14 (19)%, 12 (21)% and 26 (17)% after pretreatment with formoterol, salmeterol, and placebo, respectively (fig 3). Thirty minutes after inhaling salbutamol the increase in FEV\textsubscript{1} was still significantly smaller after both active pretreatments than after placebo (p=0.0001, ANCOVA), with again no significant difference between the two active treatments. Following all three pretreatments the mean FEV\textsubscript{1} returned to

<table>
<thead>
<tr>
<th></th>
<th>PC\textsubscript{20} methacholine (mg/ml)</th>
<th>PD\textsubscript{30+} methacholine (mg)</th>
<th>Recovery time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formoterol (n=17)</td>
<td>2.23 (1.6 to 3.1)*</td>
<td>2.48 (0.38–25.6)*</td>
<td>30.6 (21 to 45)*</td>
</tr>
<tr>
<td>Salmeterol (n=16)</td>
<td>1.59 (1.1 to 2.3)*</td>
<td>1.58 (0.28–6.4)*</td>
<td>25.8 (17 to 39)*</td>
</tr>
<tr>
<td>Placebo (n=16)</td>
<td>0.81 (0.57 to 1.1)</td>
<td>0.74 (0.08–4.8)</td>
<td>6.9 (4.5 to 10)</td>
</tr>
</tbody>
</table>

Values are geometric mean (95% CI) for PC\textsubscript{20} and recovery time, and geometric mean (range) for PD\textsubscript{30+}. Values for recovery time above 60 minutes arbitrarily set at 75 minutes.

PC\textsubscript{20} = concentration of methacholine provoking a decrease in FEV\textsubscript{1} of 20%; PD\textsubscript{30+} = cumulative dose of methacholine provoking a decrease in FEV\textsubscript{1} of \geq 30%.

*p<0.05 compared with placebo; #p<0.05 compared with salmeterol.

Figure 3 Increase in FEV\textsubscript{1} three minutes after inhalation of 50 µg salbutamol via Turbuhaler as percentage of the lowest FEV\textsubscript{1}. Salbutamol was inhaled immediately after reaching a methacholine induced decrease in FEV\textsubscript{1} of \geq 30% about one hour after the last dose of either formoterol 24 µg twice daily via Turbuhaler, salmeterol 100 µg twice daily via Diskhaler, or placebo via both devices for 2 weeks. (A) Individual values; (B) mean values and 95% confidence intervals.
the same value within 30 minutes after the inhalation of ipratropium bromide. The recovery time is shown in table 3. After pretreatment with both long acting β2 agonists recovery was significantly slower than after placebo pretreatment (p=0.0001), but the difference between formoterol and salmeterol was not significant (p=0.55). Geometric mean recovery times were 35, 28, and 7 minutes after formoterol, salmeterol and placebo, respectively.

Compliance with drug intake was more than 80% for both inhalers in all three study periods. Adverse events were reported by seven of 18 patients treated with formoterol, five of 17 treated with salmeterol, and seven of 18 following treatment with placebo. Besides respiratory symptoms and airway infections, five patients reported headache, four tremor, and one palpitations.

**Discussion**

This study shows that the magnitude of effect of salbutamol is equally decreased and its onset equally delayed following pretreatment with both formoterol and salmeterol in patients using inhaled glucocorticosteroids. This observation is not due to the difference in partial agonist properties of the two long acting β2 agonists since no difference between the two drugs was observed. However, despite using equipotent doses—which was also shown by similar and probably maximal bronchodilatation with the two drugs—formoterol had a stronger bronchoprotective effect than salmeterol when more than 20% bronchoconstriction was induced. This confirms in vitro findings that formoterol has a greater intrinsic activity and is a fuller agonist than salmeterol, especially in contracted bronchi.7 8 A similar stronger bronchoprotective effect of formoterol was also shown recently in a clinical study using high single doses.22

To the best of our knowledge, this study is the first to compare the bronchodilator response of salbutamol during regular treatment with the two long acting β2 agonists formoterol and salmeterol in the same patients using methacholine provocation to mimic a moderate to severe asthma attack.

We used high doses of formoterol and salmeterol and treatment lasted for 14 days to provide maximum stimulation of the β2 receptor and to establish a situation in which tolerance was likely.7 The methacholine provocation test was performed 1 hour after administration of the last dose of formoterol and salmeterol, when the effects of formoterol and salmeterol were expected to be maximal and when a potential antagonistic property, reflected as a difference in response to the additional salbutamol, would be most apparent.

Salbutamol was chosen to reverse methacholine induced bronchoconstriction rather than fenoterol because salbutamol is the most widely used rescue medication, despite the fact that fenoterol is a fuller agonist.9 10 The dose of salbutamol used may appear to be low but, when inhaled via a Turbuhaler, a 50 µg dose of salbutamol has been reported to be equipotent to 200 µg by Rotahaler or Diskhaler9 15 or 100 µg by metered dose inhaler22 and has been shown to be effective during acute bronchoconstriction.7 A single dose was used to increase the likelihood of detecting small differences between the two long acting β2 agonists.

At the time of salbutamol inhalation the mean FEV1 had decreased by 39%, corresponding to a moderate to severe asthma attack. After pretreatment with placebo there was a rapid onset of salbutamol action as shown in a previous study.9 However, a decreased response to inhaled salbutamol, expressed both in magnitude and as recovery time, was observed after both active treatments with no difference between the two treatments.

The observed lower sensitivity to inhaled salbutamol may have several causes. Firstly, there is evidence that continuous treatment with long acting β2 agonists leads to a reduction in their bronchoprotective effect to a number of bronchoconstricting stimuli.23–25 This loss of bronchoprotective effect is due to β2 receptor downregulation (tolerance) which is associated with subsensitivity to salbutamol, as shown in this study. This tolerance can only have been induced by the long acting β2 agonists since no additional β2 rescue medication was used during the study period. There is, however, controversy about the development of the diminished bronchodilator effect of salbutamol after long term treatment with long acting β2 agonists, as shown in our study. Some studies have found that bronchodilator subsensitivity to cumulative doses of salbutamol may be induced after continuous treatment with long acting β2 agonists, as shown by an increase in FEV1, from baseline,11–13 15 with no induction of subsensitivity after long term treatment with formoterol.13 Others have determined the absolute values of lung function16–18 and found no reduction in the sensitivity to the bronchodilating effects of salbutamol. Probable explanations are differences in baselines16–15 and in the time of the last dose of long acting β2 agonist (within 12 hours17 19 or after 12 hours11–15 19). Also, unlike this study, concomitant β2 agonist rescue medication was used during placebo treatment in some studies17 18 and some remaining β2 receptor stimulation may have induced the reduced sensitivity. In none of these studies was the methacholine provocation test model used. The justification for distinguishing tolerance between the bronchodilator and bronchoprotective response has been questioned. The methacholine provocation test has recently been used to show that continuous treatment with short acting β2 agonists induces bronchodilator tolerance,22 something that other methods had previously failed to do.27 28 In this situation of increased bronchomotor tone, relaxation of airway smooth muscle may require more β2 receptor activity and tolerance is easier to demonstrate.29 It seems likely that continuous treatment with long acting β2 agonists will also lead to tolerance in bronchodilating response, similar to the loss of bronchoprotective effect seen previously. Secondly, in the present study the methacholine provocation test was performed at the peak of the agonist response. This may have obscured the effects of salbutamol because of...
the high degree of receptor occupancy induced. It was previously been shown that inhaled formoterol (72 µg) and salmeterol (300 µg) antagonised extrapulmonary β₂ receptor mediated responses to inhaled fenoterol,²⁹ while a single, much lower dose (formoterol 12 µg, salmeterol 25 µg) had no such significant effects.³⁰ This indicates that, in the latter situation, a lower degree of receptor occupancy occurred and this did not interfere with fenoterol.

Thirdly, after active treatment a higher dose of methacholine was administered which may have led to a slower recovery in FEV₁. When tested in the ANCOVA, however, the PDₐ₉₀ was not a significant covariate.

The relative contribution of the partial agonist property, β₂ receptor downregulation, and receptor occupancy to the observed diminished response to salbutamol could not be assessed in this study. As we did not study spontaneous recovery with placebo as rescue medication, the exact additional effect of salbutamol could not be determined. Furthermore, we did not investigate the effect of salbutamol after a single dose of the two long acting β₂ agonists simultaneously. These measurements may have provided additional information with regard to the partial antagonistic properties and the development of tolerance. It is possible that the effects of receptor occupancy and tolerance may have overshadowed the effect of partial antagonism in the present study. The almost identical recovery time following the two active treatments may have been a consequence of this and may be a reason why no clinically relevant contribution resulting from the partial β₂ antagonistic property of salmeterol (to the additionally inhaled salbutamol) during maintenance treatment could be demonstrated.

These results differ from in vitro findings where salmeterol appeared to antagonise the relaxation of cholinergically contracted human bronchi induced by other β₂ agonists such as salbutamol.¹³ The in vitro study also differed from our in vivo study in that the bronchi were contracted first, then incubated with salmeterol, formoterol or placebo and the dose response curve to salbutamol produced while, in our study, the bronchi were contracted after dosing with salmeterol, formoterol, and placebo. The present study more closely mimics the clinical situation where patients are using long acting β₂ agonists and, despite this, experience an asthma attack; this is clinically more relevant than β₂ agonist naive patients experiencing bronchoconstriction and then being treated with two simultaneous β₂ agonists for reversal.

Additional studies are needed to assess interactions between long acting and short acting β₂ agonists after a longer interval such as 12 hours from administration of the long acting β₂ agonists when the bronchodilation and bronchoprotection of the long acting drug is submaximal. It would be expected that, at this time, patients are more vulnerable to an attack of bronchospasm requiring additional salbutamol rescue therapy.

This study shows that, after pretreatment with long acting β₂ agonists, the bronchodilating effect of a single dose of salbutamol is diminished, both in magnitude and onset. With a higher dose of salbutamol this phenomenon may have been missed. Indeed, in a recent study a higher dose of salbutamol was found to overcome terbutaline induced tachyphylaxis in a methacholine provocative test.³⁹ However, a high dose of salbutamol did not overcome bronchoprotective subsensitivity in asthmatic patients receiving a single dose⁴⁰ or regular treatment with salmeterol or formoterol,⁴¹ although in these latter studies some interaction caused by receptor occupancy may have occurred.

The present study shows that formoterol has a greater intrinsic activity than salmeterol. Theoretically, stronger β₂ receptor stimulation may lead to a stronger tendency towards desensitisation. If this occurred, it would have resulted in a decreased effect on the FEV₁, 12 hours after the previous dose and/or a poorer immediate response in FEV₁ and PC₂₀ after inhalation of the study medication. It would also have led to a diminished effect of salbutamol. However, we found small and insignificant differences between the two long acting β₂ agonists on FEV₁ before methacholine provocation, a significantly stronger protective effect against methacholine after formoterol compared with salmeterol, and an equally diminished response to inhaled salbutamol. These results indicate that formoterol does not cause a stronger desensitisation than salmeterol or, if it does, any difference is counterbalanced by the antagonist activity of salmeterol.

In summary, the present study did not confirm in vivo the observed in vitro findings of differences in (partial) antagonistic activities between salmeterol and formoterol. However, a higher intrinsic activity of formoterol was demonstrated in contracted bronchi which indicates that salmeterol is a partial agonist compared with formoterol in human airways in vivo in moderate to severe asthma attacks. The efficacy of an additional single dose β₂ agonist is decreased in a situation of moderate to severe methacholine induced bronchoconstriction after pretreatment with formoterol and salmeterol. This suggests that patients on regular long acting β₂ agonist treatment should be aware that a single dose of salbutamol may become less effective during an acute asthma attack.

The authors thank M Boorsma for help in designing, monitoring and analysing the study, AstraZeneca R&D Lund for preparing blinded medication, Professor J Zaagsma for critically reviewing the manuscript and G D Nossent, M P Politiek, L H Steenhuis, W J Snoek, C G Tol, and S H Wills for contributions to the clinical part of the study.

The study was supported by a research grant from AstraZeneca, the Netherlands.

Salbutamol in methacholine induced bronchoconstriction

et al


